

2. Objective

The objective of this study deals with minimising the resistance towards the TB therapy by modifying the dosage form design so that the drug-drug interactions between rifampicin and isoniazid can be prevented by formulating polymeric once-daily oral multiparticulate drug delivery systems of rifampicin and isoniazid, which facilitates the:

- Segregated delivery of these drugs for improved rifampicin stability.
- Site-specific release of rifampicin and isoniazid in gastric and intestinal conditions.
- Reduction in concentration dependent degradation of rifampicin in gastric conditions.